Natera (NASDAQ:NTRA) Stock: Insider John Fesko Sells 898 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 898 shares of the business’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total value of $382,853.32. Following the sale, the insider directly owned 195,578 shares in the company, valued at $83,382,724.52. This trade represents a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The shares were sold at an average price of $267.99, for a total value of $79,057.05.

Natera Trading Down 5.0%

NTRA opened at $414.30 on Friday. The stock has a 50-day moving average of $377.06 and a 200-day moving average of $266.44. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period in the prior year, the company earned ($0.74) EPS. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. As a group, equities research analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Natera in the second quarter valued at approximately $2,962,770,000. Bank of America Corp DE acquired a new position in Natera in the second quarter valued at $199,960,000. Legal & General Group Plc acquired a new stake in Natera during the 2nd quarter worth about $150,143,000. Bank of New York Mellon Corp acquired a new stake in Natera during the 2nd quarter worth about $149,278,000. Finally, Avala Global LP bought a new position in shares of Natera in the 2nd quarter worth about $124,867,000. 99.90% of the stock is owned by institutional investors.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Rothschild & Co Redburn initiated coverage on Natera in a research report on Tuesday, September 8th. They set a “buy” rating and a $385.00 price target on the stock. Finally, Canaccord Genuity Group raised their price target on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a report on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.